Neuphoria Therapeutics Inc.
Neuphoria Therapeutics Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Financial statements beyond 3 years are for subscribers only. Unlock 17+ years of income statements, balance sheets, and cash flow statements Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | |||||||||||||
Cash And Cash Equivalents At Carrying Value | 19 | 22 | 14 | 14 | 17 | 4 | 8 | 13 | |||||
Accounts Receivable Net Current | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Restricted Cash Current | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Prepaid Expense Current | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | |||||
Assets Current | 22 | 23 | 14 | 15 | 17 | 4 | 8 | 13 | |||||
Property Plant And Equipment Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Intangible Assets Net Excluding Goodwill | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | |||||
Operating Lease Right Of Use Asset | - | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Goodwill | 9 | 9 | 9 | 9 | 8 | 8 | 9 | 9 | |||||
Assets | 35 | 37 | 27 | 29 | 31 | 18 | 23 | 28 | |||||
Liabilities Current | |||||||||||||
Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | |||||
Accrued Liabilities And Other Liabilities | 1 | 2 | 4 | 3 | 1 | 0 | 1 | 1 | |||||
Operating Lease Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Liabilities Current | 2 | 3 | 5 | 4 | 2 | 2 | 3 | 4 | |||||
Operating Lease Liability Noncurrent | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Business Combination Contingent Consideration Liab… | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | |||||
Deferred Income Tax Liabilities Net | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | |||||
Warrants And Rights Outstanding | 2 | 3 | 8 | 4 | 2 | 1 | 2 | 5 | |||||
Other Liabilities Noncurrent | - | - | - | - | 0 | 0 | 0 | 0 | |||||
Liabilities | 5 | 7 | 15 | 10 | 5 | 4 | 6 | 10 | |||||
Stockholders Equity | |||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | |||||
Additional Paid In Capital | 218 | 218 | 204 | 200 | 199 | 198 | 198 | 198 | |||||
Accumulated Other Comprehensive Income Loss Net Of… | -2 | -2 | -3 | -3 | -4 | -4 | -2 | -3 | |||||
Retained Earnings Accumulated Deficit | -187 | -186 | -188 | -178 | -169 | -181 | -179 | -178 | |||||
Stockholders Equity | 29 | 30 | 13 | 19 | 26 | 14 | 17 | 17 | |||||
Liabilities And Stockholders Equity | 35 | 37 | 27 | 29 | 31 | 18 | 23 | 28 | |||||
Common Stock Par Or Stated Value Per Share | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | |||||
Common Stock Shares Issued | 5 | 5 | 2 | 2 | 2 | 2 | 3 | 1 | |||||
Shares Outstanding | 5 | 5 | 2 | 2 | 2 | 2 | 3 | 1 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -10.86% | -20.25% | -16.08% | 11.82% | 17.73% | 30.79% | -5.07% | -28.54% | -17.97% | - | - | - |
| 2025 | -5.68% | -10.62% | 39.33% | 11.34% | 4.45% | 2.33% | 26.22% | 42.41% | 37.59% | -47.39% | -62.39% | -67.20% |
| 2024 | - | - | - | - | - | - | - | - | - | -43.74% | -32.80% | -44.65% |
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Neuphoria Therapeutics Inc. (NEUP) — SEC Financial Statements & Analysis
Neuphoria Therapeutics Inc. (NEUP) is a pharmaceutical preparations company, incorporated in C3. Neuphoria Therapeutics Inc. trades on Nasdaq as: NEUP. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Neuphoria Therapeutics Inc. reported a -100.08% year-over-year revenue growth, a Debt-to-Equity ratio of 0.18x, a Price-to-Sales (P/S) ratio of -1660.04x (TTM), a Price-to-Book (P/B) ratio of 0.75x (TTM), at a market cap of $22.02M. Figures below are sourced from SEC EDGAR, as-filed.
- Net Revenue TTM Growth 1Y
- -100.08%
- Debt To Equity
- 0.18x
- P/S TTM
- -1660.04x
- P/B TTM
- 0.75x
- Market Cap
- $22.02M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Neuphoria Therapeutics Inc. in?
Neuphoria Therapeutics Inc. (NEUP) operates in the Pharmaceutical Preparations industry.
What is NEUP's market cap?
Neuphoria Therapeutics Inc. (NEUP) has a market capitalization of $22.02M as of 2026-03-31.
What exchange does NEUP trade on?
Neuphoria Therapeutics Inc. (NEUP) trades on the Nasdaq.
Where is Neuphoria Therapeutics Inc. incorporated?
Neuphoria Therapeutics Inc. is incorporated in Australia.